Streetbeat News

Products Services

TNXP

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) announced its transition to a fully integrated biopharmaceutical company by April 1, 2024. This follows the acquisition of Zembrace® SymTouch® and Tosymra®, both migraine treatments. Tonix aims to market these products through its subsidiary, Tonix Medicines, and prepare for the potential 2025 launch of Tonmya™ for fibromyalgia, pending FDA approval. The company is enhancing its commercial capabilities, including distribution, marketing, and regulatory aspects.

Portfolio Pulse from Benzinga Newsdesk

March 19, 2024 | 12:04 pm

IVDA

Iveda (NASDAQ:IVDA) expands its partnership with Evergreen Aviation Technologies Corp. (EGAT) to deploy military-grade smart drones globally for surveillance and security. The partnership, valued over $2.5 million, aims to develop drones equipped with Iveda's AI Video Analytics for various applications including military deployments and disaster surveillance. This expansion follows successful collaborations and responds to multiple RFPs from private and government entities. Iveda's growth is further highlighted by new partnerships and international expansions, including a $3.2M contract with the Taiwanese government.

Portfolio Pulse from Benzinga Newsdesk

March 19, 2024 | 12:03 pm

SPIR

Spire Global's stock is trading higher following the announcement of a collaboration with NVIDIA to enhance AI-driven weather prediction capabilities.

Portfolio Pulse from Benzinga Newsdesk

March 19, 2024 | 11:57 am

CMND

Clearmind Medicine Inc., a biotech company specializing in psychedelic-derived therapeutics, announced receiving divisional patent approval in China from the China National Intellectual Property Administration for its treatments.

Portfolio Pulse from Benzinga Newsdesk

March 19, 2024 | 11:56 am

ENVB

Enveric Biosciences shares surged following the announcement of two non-binding term sheets signed with an undisclosed biotech company for out-licensing cannabinoid-COX-2 conjugate compounds for treating joint diseases.

Portfolio Pulse from Benzinga Newsdesk

March 19, 2024 | 11:47 am

AMD

COIN

FUSN

NVDA

SNPS

US stock futures indicate a lower opening due to Fed meeting concerns and the Bank of Japan's policy shift. Tech stocks like Nvidia and Apple had previously boosted the market, but pre-Fed jitters and a lack of major catalysts are dampening sentiment. Nvidia, AMD, and Synopsys saw notable premarket movements, while Coinbase and Robinhood dropped with Bitcoin. Fusion Pharmaceuticals surged on an AstraZeneca buyout deal. Oil paused its rally, and global markets showed mixed responses.

Portfolio Pulse from Shanthi Rexaline

March 19, 2024 | 11:41 am

CWI

INTC

SOXX

TSM

Taiwan Semiconductor Manufacturing Co (TSM) and Intel Corp (INTC) face construction delays in Arizona due to high costs and labor shortages, impacting their efforts to strengthen the U.S. semiconductor supply chain. Suppliers like LCY Chemical and Solvay have paused or downscaled their plans, citing increased expenses and operational challenges. This situation reflects broader issues in expanding the U.S. chip supply, with costs significantly higher than in Asia. TSMC and Samsung are also adjusting their global expansion strategies due to these challenges. TSMC's stock has risen 52% due to the AI boom, with exposure available through ETFs like SOXX and CWI.

Portfolio Pulse from Anusuya Lahiri

March 19, 2024 | 11:32 am

AZN

BMY

FUSN

LLY

AstraZeneca Plc (NASDAQ:AZN) has agreed to acquire Fusion Pharmaceuticals Inc (NASDAQ:FUSN) for $21.00 per share in cash, plus a contingent value right of $3.00 per share, totaling a potential $2.4 billion transaction. This acquisition signifies AstraZeneca's shift towards more targeted cancer treatments, specifically through radioconjugates (RCs), enhancing its oncology portfolio. The deal includes Fusion's cash assets and complements AstraZeneca's ambition to transform cancer treatment. Additionally, recent acquisitions by Bristol Myers Squibb & Co (NYSE:BMY) and Eli Lilly And Co (NYSE:LLY) highlight the industry's focus on targeted therapies.

Portfolio Pulse from Vandana Singh

March 19, 2024 | 11:26 am

NVDA

SPIR

Spire Global Inc (SPIR) shares surged after announcing a collaboration with NVIDIA Corp (NVDA) to enhance AI-driven weather prediction using Spire's satellite data and NVIDIA's AI technology. The partnership aims to improve climate and weather forecasting accuracy, benefiting Spire's core products like the DeepVision weather risk mitigation platform, maritime route optimization, and renewable energy forecasts.

Portfolio Pulse from Shivani Kumaresan

March 19, 2024 | 11:25 am

NVDA

SPIR

Spire Global has entered into a collaboration with NVIDIA to advance AI-driven weather prediction. This partnership aims to leverage NVIDIA's AI technology to enhance weather forecasting accuracy and efficiency.

Portfolio Pulse from Benzinga Newsdesk

March 19, 2024 | 11:25 am